Product Description: HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor targeting HER3. HMBD-001 inhibits the dimerization of HER3 and inhibits the growth, proliferation and other activities of tumor cells. HMBD-001 is promising for research of cancers, such as pancreatic cancer and non-small cell lung cancer[1][2].
Formula: N/A
References: [1]Pavlakis N, et al. 88TiP A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling[J]. Annals of Oncology, 2023, 34: S1501./[2]Idowu O, et al. 688P Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours[J]. Annals of Oncology, 2023, 34: S480.
Molecular Weight: N/A
Research Area: Cancer
Target: EGFR
English
Deutsch
